IPN-01087

N/A

Report date: 2025/09/24 17:41:51
NME

Base Information

Drug NameIPN-01087
Drug Alias Name177Lu-IPN01087[177Lu]3BP-227[177Lu]IPN-01087177Lu-3BP-227IPN 01087 +[10] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionNeurotensin receptor 1 agonistsRadionuclide imaging enhancers
TargetsNeurotensin receptor 1
Therapy Area/IndicationsNeoplasm MetastasisStomach NeoplasmsColorectal Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator Companies3B Pharmaceuticals GmbH
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesFusion Pharmaceuticals IncIpsen
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisStomach NeoplasmsColorectal Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksN/A